keyword
MENU ▼
Read by QxMD icon Read
search

Hbsag

keyword
https://www.readbyqxmd.com/read/28543299/low-occurrence-of-hbsag-but-high-frequency-of-transient-occult-hbv-infection-in-vaccinated-and-hbig-administered-infants-born-to-hbsag-positive-mothers
#1
Shan Zhou, Tingting Li, Jean-Pierre Allain, Bin Zhou, Yuming Zhang, Mei Zhong, Yongshui Fu, Chengyao Li
The status of chronic and occult HBV infection (OBI) in neonatal hepatitis B vaccine and immunoglobulin (HBIG) vaccinated infants born to HBsAg+ mothers was investigated at a major hospital in China. Seventy-seven and 15 blood samples were collected in first or second follow-up detection from the vaccinated babies aged 3 to 36 months born to 43 HBsAg+ or plus 25 HBeAg+ mothers. HBV infection was analyzed between the paired baby and mother by serology and DNA analysis. Among 77 children born to 68 HBsAg+ mothers, 3...
May 23, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28540167/t-cell-associated-immunoregulation-and-antiviral-effect-of-oxymatrine-in-hydrodynamic-injection-hbv-mouse-model
#2
Xiuxiu Sang, Ruilin Wang, Yanzhong Han, Cong'en Zhang, Honghui Shen, Zhirui Yang, Yin Xiong, Huimin Liu, Shijing Liu, Ruisheng Li, Ruichuang Yang, Jiabo Wang, Xuejun Wang, Zhaofang Bai, Xiaohe Xiao
Although oxymatrine (OMT) has been shown to directly inhibit the replication of hepatitis B virus (HBV) in vitro, limited research has been done with this drug in vivo. In the present study, the antiviral effect of OMT was investigated in an immunocompetent mouse model of chronic HBV infection. The infection was achieved by tail vein injection of a large volume of DNA solution. OMT (2.2, 6.7 and 20 mg/kg) was administered by daily intraperitoneal injection for 6 weeks. The efficacy of OMT was evaluated by the levels of HBV DNA, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B core antigen (HBcAg)...
May 2017: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/28537061/dolutegravir-lamivudine-as-initial-therapy-in-hiv-1-infected-arv-naive-patients-48-week-results-of-the-paddle-pilot-antiretroviral-design-with-dolutegravir-lamivudine-study
#3
Pedro Cahn, María José Rolón, María Inés Figueroa, Ana Gun, Patricia Patterson, Omar Sued
INTRODUCTION: A proof-of-concept study was designed to evaluate the antiviral efficacy, safety and tolerability of a two-drug regimen with dolutegravir 50 mg once daily (QD) plus lamivudine 300 mg once daily as initial highly active antiretroviral therapy (HAART) among antiretroviral (ARV)-naive patients. METHODS: PADDLE is a pilot study including 20 treatment-naive adults. To be selected, participants had no IAS-USA-defined resistance, HIV-1 RNA ≤100,000 copies/mL at screening and negative HBsAg...
May 9, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28533877/-prevalence-of-hepatitis-b-surface-antigen-and-its-associated-factors-in-senegalese-military-personnel-sent-on-mission-to-darfur
#4
Moustapha Diop, Assane Diouf, Said Malaobé Seck, Gora Lo, Daye Ka, Aminata Massaly, Alassane Dieye, Ndeye Maguette Fall, Viviane Marie Pierre Cisse-Diallo, Khardiata Diallo-Mbaye, Ndèye Aissatou Lakhe, Louise Fortes-Déguénonvo, Cheikh Tidiane Ndour, Maserigne Soumaré, Moussa Seydi
INTRODUCTION: In Senegal, 85% of the adult population have been exposed to the hepatitis B virus and about 11% of them are chronic surface antigen (HBsAg) carriers. This infection is poorly documented among Senegalese Armed Forces. The aim of this study was to assess the prevalence of HBsAg in Senegalese military personnel on mission to Darfur (Sudan) and to identify its associated factors. METHODS: We conducted a cross-sectional study among Senegalese military personnel stationed in Darfur from 1 July 2014 to 31 July 2014...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28523053/seroprevalence-of-transfusion-transmitted-infections-among-different-blood-group-donors-at-blood-bank-lumhs-hyderabad
#5
Faheem Ahmed Memon, Ikram Din Ujjan, Amir Iqbal Memon, Abdul Rehman Shaikh, Ali Raza Rao, Arshi Naz
OBJECTIVES: To study the prevalence of HBsAg, Anti-HCV, HIV, Syphilis and Malaria in blood donors. METHODS: This is a cross sectional descriptive study, conducted at Blood bank and Transfusion center at Liaquat University of Medical & Health Sciences (LUMHS) Hyderabad, during the period from January, 2014 to June, 2015. A total of 4683 blood donors were screened for HBsAg, Anti-HCV and HIV on Architect 20001 (manufactured by Abbott), employing chemiluminescent microparticle immunoassay (CMIA)...
March 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28522427/association-of-chitosan-and-aluminium-as-a-new-adjuvant-strategy-for-improved-vaccination
#6
F Lebre, D Bento, J Ribeiro, M Colaço, G Borchard, M C Pedroso de Lima, O Borges
The use of particulate adjuvants offers an interesting possibility to enhance and modulate the immune responses elicited by vaccines. Aluminium salts have been extensively used as vaccine adjuvants, but they lack the capacity to induce a strong cellular and mucosal immune response. Taking this into consideration, in this study we designed a new antigen delivery system combining aluminium salts with chitosan. Chitosan-aluminium nanoparticles (CH-Al NPs) exhibited a mean diameter of 280nm and a positive surface charge...
May 15, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28522204/peg-interferon-plus-nucleotide-analogue-treatment-versus-no-treatment-in-patients-with-chronic-hepatitis-b-with-a-low-viral-load-a-randomised-controlled-open-label-trial
#7
Annikki de Niet, Louis Jansen, Femke Stelma, Sophie B Willemse, Sjoerd D Kuiken, Sebastiaan Weijer, Carin M J van Nieuwkerk, Hans L Zaaijer, Richard Molenkamp, R Bart Takkenberg, Maarten Koot, Joanne Verheij, Ulrich Beuers, Hendrik W Reesink
BACKGROUND: Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen [anti-HBs]). We assessed HBsAg loss during peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in patients with chronic hepatitis B with a low viral load. METHODS: In this randomised controlled, open-label trial, patients were enrolled from the Academic Medical Center (AMC), Amsterdam, Netherlands...
May 15, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28521640/antibody-mediated-immunotherapy-against-chronic-hepatitis-b-virus-infection
#8
Ying Gao, Tian-Ying Zhang, Quan Yuan, Ning-Shao Xia
The currently available drugs to treat hepatitis B virus (HBV) infection include interferons and nucleos(t)ide analogues, which can only induce disease remission and are inefficient for the functional cure of patients with chronic HBV infection (CHB). Since high titers of circulating hepatitis B surface antigen (HBsAg) may be essential to exhaust the host anti-HBV immune response and they cannot be significantly reduced by current drugs, new antiviral strategies aiming to suppress serum hepatitis B surface antigen (HBsAg) could help restore virus-specific immune responses and promote the eradication of the virus...
May 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28521532/new-antivirals-for-the-treatment-of-chronic-hepatitis-b
#9
Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M Peña, Carmen de Mendoza
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered: New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription...
May 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28520708/hepatitis-b-surface-antigen-screening-among-pregnant-women-and-care-of-infants-of-hepatitis-b-surface-antigen-positive-mothers-guam-2014
#10
Winston E Abara, Susan Cha, Tasneem Malik, Mia S DeSimone, Bernadette Schumann, Esther Mallada, Michael Klemme, Vince Aguon, Anne Marie Santos, Melissa Collier, Mary Kamb
Hepatitis B virus (HBV) infection is endemic among adults in the U.S. territory of Guam (1,2). Perinatal HBV transmission, which occurs at birth from an infected mother to her newborn infant, is a major mode of HBV transmission and maintains HBV endemicity (3). Approximately 90% of HBV-infected infants will develop chronic HBV infection, and approximately 25% of those will die prematurely from liver failure or hepatocellular carcinoma (4,5). Since 1988, the Advisory Committee on Immunization Practices has recommended that all pregnant women be screened for hepatitis B surface antigen (HBsAg), an indicator of HBV infection, and that infants of women who screen positive (HBsAg-positive women) receive postexposure prophylaxis (PEP) (hepatitis B vaccine and hepatitis B immunoglobulin [HBIG])...
May 19, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28518219/impact-of-the-timing-of-hepatitis-b-virus-identification-and-anti-hepatitis-b-virus-therapy-initiation-on-the-risk-of-adverse-liver-outcomes-for-patients-receiving-cancer-therapy
#11
Jessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, Andrea Barbo, Heather Y Lin, Sairah Ahmed, Mariana Chavez-MacGregor, Christian Donato-Santana, Cathy Eng, Alessandra Ferrajoli, Michael J Fisch, Peter McLaughlin, George R Simon, Gabriela Rondon, Elizabeth J Shpall, Anna S Lok
BACKGROUND: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface antigen [HBsAg]-positive/hepatitis B core antibody [anti-HBc]-positive) or past (HBsAg-negative/anti-HBc-positive) hepatitis B virus (HBV) after chemotherapy. This study was aimed at determining the impact of test timing and anti-HBV therapy on adverse liver outcomes in these patients. METHODS: Patients with solid or hematologic malignancies who received chemotherapy between 2004 and 2011 were retrospectively studied...
May 18, 2017: Cancer
https://www.readbyqxmd.com/read/28513915/impact-of-a-determinant-mutations-on-detection-of-hepatitis-b-surface-antigen-hbsag-in-hbv-strains-from-chinese-patients-with-occult-hepatitis-b
#12
Xiangyan Huang, Chenyun Ma, Qiang Zhang, Qingfen Shi, Tao Huang, Chao Liu, Jie Li, F Blaine Hollinger
This study was designed to detect mutations that occur within the "a" determinant in the S gene of the hepatitis B virus (HBV) in patients with occult hepatitis B (OHB), and to analyze the influence of these mutations on expression and reactivity of the hepatitis B surface antigen (HBsAg). Twenty-three certified OHB samples were compared to 32 HBsAg positive samples from patients with chronic hepatitis B. The median HBV DNA levels in the OHB group were significantly lower than those in the control group (p < 0...
May 17, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28513813/hepatitis-b-virus-reactivation-after-effective-sofosbuvir-and-ribavirin-treatment-in-a-patient-with-occult-hepatitis-b-virus-infection
#13
Silvia Odolini, Paola Lanza, Angiola Angiola, Serena Zaltron, Lucia Urbinati, Andrea Vavassori, Paola Nasta, Elena Festa, Franco Gargiulo, Anna Rodella, Arnaldo Caruso, Salvatore Casari, Francesco Castelli, Mauro Viganò
Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC...
May 17, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28506632/evaluation-of-hbsag-and-anti-hbc-assays-in-saliva-and-dried-blood-spot-samples-according-hiv-status
#14
Geane Lopes Flores, Helena Medina Cruz, Denise Vigo Potsch, Silvia Beatriz May, Carlos Eduardo Brandão-Mello, Marcia Maria Amendola Pires, Jose Henrique Pilotto, Lia Laura Lewis-Ximenez, Elisabeth Lampe, Livia Melo Villar
Influence of HIV status in HBV markers detection in saliva and dried blood spots (DBS) was not well established. This study aims to evaluate the performance of optimized commercial immunoassay for identifying HBsAg and anti-HBc in saliva and DBS according HIV status. A sum of 535 individuals grouped as HIV(+), HBV(+), HIV/HBV(+) and HIV/HBV- were recruited where 347 and 188 were included for HBsAg and anti-HBc evaluation, respectively. Serum, DBS collected in Whatman 903 paper and saliva obtained using salivette device were analyzed using EIA...
May 12, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28505202/serum-hbv-surface-antigen-positivity-is-associated-with-low-prevalence-of-metabolic-syndrome-a-meta-analysis
#15
Yuanyuan Li, Ying Zhao, Jianping Wu
BACKGROUND AND AIM: As there is conflicting evidence for the relationship between hepatitis B virus surface antigen (HBsAg) positivity and the prevalence of metabolic syndrome (MetS), we performed a meta-analysis to investigate whether HBsAg positivity affects the incidence of MetS. METHODS: Observational studies on the relationship between HBsAg positivity and MetS were obtained from PubMed, Web of Science, and the Cochrane Library in April 2016. The pooled odds ratios (ORs) of MetS and its components (central obesity, increased fasting glucose, increased blood pressure, dyslipidemia) for subjects with or without HBsAg positivity were synthesized...
2017: PloS One
https://www.readbyqxmd.com/read/28504115/protocatechuic-acid-inhibits-hepatitis-b-virus-replication-by-activating-erk1-2-pathway-and-down-regulating-hnf4%C3%AE-and-hnf1%C3%AE-in-vitro
#16
Xiao-Qing Dai, Wen-Tao Cai, Xiao Wu, Yong Chen, Feng-Mei Han
AIMS: Protocatechuic acid (PCA) is a phenolic compound found in many antiviral Chinese herbal medicines. HNF4α and HNF1α, the members of hepatocyte nuclear factor (HNF) family, play an important regulatory role in the gene transcription of hepatitis B virus (HBV). Previous studies found that PCA inhibited HBV antigen secretion and HBV DNA replication in HepG2.2.15 cells, but its anti-HBV mechanism has not been fully understood. We aim to illustrate the anti-HBV mechanism of PCA. MATERIALS AND METHODS: MTT was used to estimate cytotoxicity...
May 12, 2017: Life Sciences
https://www.readbyqxmd.com/read/28500636/immune-correlates-of-hepatitis-b-surface-antigen-spontaneous-seroconversion-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients
#17
Ashish Kumar Vyas, Barjesh Chander Sharma, Shiv Kumar Sarin, Nirupma Trehanpati
BACKGROUND: Hepatitis B surface antigen (HBsAg) seroconversion in HBeAg-ve chronic hepatitis B (CHB) infection is rare, possibly due to poor antigen processing and impaired humoral response. We investigated the role of dendritic cells (DCs), T follicular helper (TFH) cells and plasma B cells in seroconversion. METHODS: HBeAg-ve (n=135) CHB patients with raised ALT at baseline were followed-up. Patients undergoing HBsAg sero-conversion (Gr. I, n=11) were compared with non-converters with low (Gr...
May 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28500322/incidence-and-predictors-of-hbv-relapse-after-cessation-of-nucleoside-analogues-in-hbeag-negative-patients-with-hbsag%C3%A2-%C3%A2-%C3%A2-200%C3%A2-iu-ml
#18
Chih-Chien Yao, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Hung Wang, Chung-Mo Lee, Chien-Hung Chen
The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg ≤ 200 IU/mL, were treated with lamivudine (n = 34) and entecavir (n = 85). The 5-year rates of post-treatment virological relapse, clinical relapse, and HBsAg loss at 60 months were 39.4%, 27.6%, and 45...
May 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28499864/role-of-hepatitis-b-core-protein-in-hbv-transcription-and-recruitment-of-histone-acetyltransferases-to-cccdna-minichromosome
#19
Chun Kong Chong, Ching Yan Serene Cheng, Sin Yi Jasmine Tsoi, Fung-Yu Huang, Fen Liu, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Danny Ka-Ho Wong
The hepatitis B core protein (HBc) has been suggested to interact with covalently closed circular DNA (cccDNA) and regulate hepatitis B virus (HBV) transcription. However, direct evidence is lacking. We aimed to identify the specific HBc region(s) responsible for transcription regulation and its interaction with cccDNA. Seventeen mutants with mutations at the four arginine-rich clusters of the HBc carboxyl-terminal domain (CTD) were created. The effect of HBc mutations on the levels of HBV DNA, RNA, and hepatitis B surface antigen (HBsAg) were measured...
May 10, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28497124/parv4-prevalence-phylogeny-immunology-and-coinfection-with-hiv-hbv-and-hcv-in-a-multicentre-african-cohort
#20
Colin P Sharp, William F Gregory, Louise Hattingh, Amna Malik, Emily Adland, Samantha Daniels, Anriette van Zyl, Jonathan M Carlson, Susan Wareing, Anthony Ogwu, Roger Shapiro, Lynn Riddell, Fabian Chen, Thumbi Ndung'u, Philip J R Goulder, Paul Klenerman, Peter Simmonds, Pieter Jooste, Philippa C Matthews
Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, seroprevalence is high in the general population, but little is known about the transmission routes or the prevalence of coinfection with blood-borne viruses, HBV, HCV and HIV.  Methods: To further explore the characteristics of PARV4 in this setting, with a particular focus on the prevalence and significance of coinfection, we screened a cohort of 695 individuals recruited from Durban and Kimberley (South Africa) and Gaborone (Botswana) for PARV4 IgG and DNA, as well as documenting HIV, HBV and HCV status...
April 7, 2017: Wellcome Open Research
keyword
keyword
10874
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"